Last reviewed · How we verify
Vaginal Estrogen - Twice Weekly
Estrogen replacement therapy to alleviate menopausal symptoms.
Estrogen replacement therapy to alleviate menopausal symptoms. Used for Treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause or breast cancer treatment, Treatment of vaginal pain during sexual intercourse.
At a glance
| Generic name | Vaginal Estrogen - Twice Weekly |
|---|---|
| Also known as | Conjugated Estrogens CSD, 0.625 mg/g, Vaginal Cream |
| Sponsor | Queen's University |
| Drug class | estrogen |
| Target | estrogen receptor |
| Modality | Small molecule |
| Therapeutic area | Women's Health |
| Phase | Phase 3 |
Mechanism of action
Vaginal estrogen works by releasing estrogen directly into the vagina, which helps to restore the natural balance of estrogen in the body. This can help to alleviate symptoms such as vaginal dryness, itching, and burning, as well as hot flashes and night sweats. The exact mechanism is not fully understood, but it is thought to involve the stimulation of estrogen receptors in the vagina and surrounding tissues.
Approved indications
- Treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause or breast cancer treatment
- Treatment of vaginal pain during sexual intercourse
Common side effects
- Vaginal discharge
- Vaginal itching
- Breast tenderness
- Headache
- Nausea
Key clinical trials
- Postpartum Vaginal Estrogen for Breastfeeding Patients (PHASE4)
- Topical Vaginal Estrogen for Postpartum Obstetric Anal Sphincter Injury Recovery (PHASE4)
- Effect of Vaginal Estrogen on Alterations in the Urine Microbiome of Menopausal Women With Overactive Bladder (PHASE4)
- Adherence to Vaginal Estrogen Therapy in Hypoestrogenic Women With Recurrent Urinary Tract Infections (PHASE4)
- Er:YAG Laser Combined With Vaginal Estriol for Genitourinary Syndrome of Menopause (NA)
- The Effectiveness of Combined Pelvic Floor Muscle Training and Vaginal Oestrogen Therapy in Postmenopausal Women With Stress Urinary Incontinence (NA)
- GRACE-trial: a Randomized Active-controlled Trial for vulvovaGinal atRophy in breAst Cancer Patients on Endocrine Therapy. (PHASE4)
- Periurethral vs Intravaginal Estrogen for Prevention of Recurrent Urinary Tract Infections (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vaginal Estrogen - Twice Weekly CI brief — competitive landscape report
- Vaginal Estrogen - Twice Weekly updates RSS · CI watch RSS
- Queen's University portfolio CI